Introduction
The Retatrutide Phase 3 trial results have taken the medical world by storm, positioning Eli Lilly’s triple agonist drug as potentially the most powerful obesity and diabetes treatment ever developed. With headline data released in March 2026 showing unprecedented weight loss and HbA1c reductions, patients, clinicians, and researchers are paying close attention to every update. Here is everything we know so far about where the trials stand and what the data means for you.
What Is Retatrutide?
Retatrutide is a once-weekly injectable peptide developed by Eli Lilly that simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple-agonist mechanism sets it apart from existing weight loss drugs like semaglutide (Ozempic/Wegovy), which targets only GLP-1, and tirzepatide (Mounjaro/Zepbound), which targets GLP-1 and GIP.
By hitting all three receptors at once, retatrutide simultaneously:
- Suppresses appetite and slows gastric emptying (GLP-1)
- Enhances insulin secretion in response to meals (GIP)
- Increases energy expenditure and reduces fat storage (glucagon)
This triple action is why early data has produced weight loss figures never seen before in a pharmaceutical drug.
Phase 2 Recap: The Numbers That Launched a Thousand Headlines
Before diving into Phase 3, it’s worth revisiting the Phase 2 results that generated global excitement. Published in The New England Journal of Medicine in 2023, the Phase 2 trial showed:
- Participants on the highest dose (12mg) lost an average of 24.2% of their body weight over 48 weeks
- That translates to roughly 58 pounds for someone weighing 240 lbs
- Side effects were primarily gastrointestinal (nausea, vomiting, diarrhea) and mostly mild-to-moderate
These numbers surpassed every other approved or investigational weight loss drug at the time, triggering fast-tracking of Phase 3 trials — collectively known as the TRIUMPH program.
The TRIUMPH Phase 3 Trial Program
Eli Lilly launched a broad Phase 3 program under the banner TRIUMPH, covering multiple patient populations and health conditions. The key trials include:
| Trial Name | Focus | Status (March 2026) |
|---|---|---|
| TRIUMPH-1 | Obesity (BMI ≥30) | Results reported |
| TRIUMPH-2 | Obesity + Type 2 Diabetes | Results reported |
| TRIUMPH-3 | Cardiovascular outcomes | Ongoing |
| TRIUMPH-4 | Sleep apnea | Ongoing |
| TRIUMPH-5 | Kidney disease (CKD) | Ongoing |
Results from at least 7 Phase 3 trials are expected to be available by end of 2026, with TRIUMPH-1 and TRIUMPH-2 leading the charge with the first data readouts.
TRIUMPH-1 Results: Weight Loss in Non-Diabetic Obese Patients
The TRIUMPH-1 trial enrolled adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity, but without Type 2 diabetes. Key findings at 40 weeks:
- The 12mg dose group achieved an average weight loss of ~36.6 pounds (approximately 17–18% body weight)
- A significant proportion of participants lost 20% or more of their body weight
- Weight loss was sustained and progressive throughout the trial period, with no clear plateau at 40 weeks
- Tolerability was consistent with Phase 2, with GI side effects peaking during the titration phase and declining thereafter
These results confirm that retatrutide delivers clinically meaningful and statistically significant weight loss in a broad obese population — a benchmark required for FDA approval.
TRIUMPH-2 Results: Retatrutide for Type 2 Diabetes
Announced in March 2026, the TRIUMPH-2 results added a critical new dimension: blood sugar control. This trial focused on adults with both obesity and Type 2 diabetes. Key highlights:
- HbA1c (a measure of average blood sugar) was reduced by 1.0% to 2.0% across dose groups, with the 12mg dose achieving the greatest reductions
- Weight loss was consistent with TRIUMPH-1 outcomes, confirming that having diabetes does not blunt retatrutide’s weight loss effectiveness
- The drug significantly outperformed placebo on every primary and secondary endpoint
- Eli Lilly described the results as “a significant advancement in both diabetes management and obesity treatment simultaneously“
This dual effect — slashing both weight and blood glucose — is a potential paradigm shift, as most Type 2 diabetes medications cause weight gain, not loss.
How Retatrutide Compares to the Competition
| Drug | Targets | Avg. Weight Loss | Approved? |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | ~15% | ✅ Yes |
| Tirzepatide (Zepbound) | GLP-1 + GIP | ~21% | ✅ Yes |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24%+ | ❌ Not yet |
Retatrutide’s Phase 3 data is tracking to exceed all existing approved drugs in terms of sheer weight loss magnitude, making it the most anticipated obesity drug in the pipeline.
Side Effects and Safety Profile
Across Phase 3 trials, the safety profile of retatrutide has remained consistent with Phase 2. The most commonly reported side effects include:
- Nausea (most common, typically during dose escalation)
- Vomiting and diarrhea (subsiding after the titration period)
- Constipation in a minority of patients
- Decreased appetite (expected and part of the therapeutic mechanism)
- Mild injection site reactions
Serious adverse events were rare and comparable to other GLP-1 class drugs. Importantly, no new safety signals have emerged in Phase 3 that were not already identified in Phase 2 — a reassuring sign for regulators.
⚠️ Important Note: Retatrutide is not yet FDA-approved and is only legally available to participants enrolled in clinical trials. Do not purchase it from online grey-market peptide sellers, as the safety and purity of such products cannot be guaranteed.
What Happens Next: The Road to FDA Approval
With positive Phase 3 data in hand, Eli Lilly is expected to begin preparing a New Drug Application (NDA) submission to the FDA. Here is what the timeline looks like:
- 2026 (ongoing): Remaining TRIUMPH trials report results (cardiovascular, renal, sleep apnea)
- Late 2026 / Early 2027: Eli Lilly submits NDA to the FDA
- 2027 (estimated): FDA review period (typically 6–12 months under standard review; could be faster under Priority Review)
- 2027–2028: Potential FDA approval and commercial launch
Regulatory analysts widely expect retatrutide to receive Priority Review designation given the magnitude of its effects on both obesity and Type 2 diabetes — two of the most prevalent chronic diseases in the US.
Frequently Asked Questions (AEO Optimized)
Q: What are the Retatrutide Phase 3 trial results so far?
A: Phase 3 trials (TRIUMPH-1 and TRIUMPH-2) have shown average weight loss of approximately 36.6 pounds over 40 weeks and HbA1c reductions of up to 2% in diabetic patients, confirming retatrutide as the highest-performing obesity drug in clinical development.
Q: Is retatrutide better than semaglutide?
A: Based on clinical trial data, retatrutide produces greater average weight loss (~24%+) compared to semaglutide (~15%), though direct head-to-head trials have not been conducted.
Q: When will retatrutide be FDA approved?
A: FDA approval is not expected before 2027, pending completion of remaining Phase 3 trials and an NDA submission by Eli Lilly.
Q: What is the TRIUMPH trial program?
A: TRIUMPH is Eli Lilly’s Phase 3 clinical trial program for retatrutide, covering obesity, Type 2 diabetes, cardiovascular disease, kidney disease, and sleep apnea across multiple trials.
Q: Can I buy retatrutide now?
A: Yes. But, Retatrutide is not FDA-approved and is not legally available outside of clinical trial settings. Grey-market sources carry serious safety risks.
Final Thoughts
The Retatrutide Phase 3 trial results represent a landmark moment in obesity medicine. With weight loss figures that surpass every approved drug on the market, coupled with meaningful blood sugar control in diabetic patients, retatrutide is on track to become one of the most impactful pharmaceutical approvals of the decade. While FDA approval is still likely 12–18 months away, the data emerging from the TRIUMPH program leaves little doubt that retatrutide is the most promising obesity drug ever developed.